Clinical trials group Icon, which is listed on the Dublin and Nasdaq stock markets, has been awarded in excess of $45 million (€52.8 million) in net new business for the fourth quarter ended May 31st, 2001.

The company has estimated that it has already booked 80 per cent of forecast revenues for the financial year ended May 31st, 2002.